EVMN (Evommune) Other Stockholders Equity: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVMN Evommune Inc EVMN
10 GF Score
Price $14.12
! 2 Warning Signs
View Full Analysis

What is Evommune Other Stockholders Equity?

Evommune EVMN -0.63% 10 Other Stockholders Equity is $0.00 Mil as of Jun. 2026. GuruFocus rates EVMN with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Evommune's Other Stockholders Equity for the quarter that ended in Jun. 2026 was $0.00 Mil.

Evommune's quarterly Other Stockholders Equity increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil) but then declined from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Evommune's annual Other Stockholders Equity stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Evommune Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Evommune's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evommune Other Stockholders Equity Chart

Evommune Annual Data
Trend Dec23 Dec24 Dec25
Other Stockholders Equity
0.00 0.00 0.00

Evommune Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
EVMN
10GF Score
Evommune Inc EVMN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evommune Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Evommune (EVMN) has a Other Stockholders Equity of $0.00 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Evommune and its competitors.
Is Evommune's Other Stockholders Equity too high?
Evommune's current Other Stockholders Equity is $0.00 Mil. Overall, Evommune has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Evommune's Other Stockholders Equity compare to OCGN and PBYI?
Evommune's Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Evommune and its competitors. Evommune's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evommune stock overvalued right now?
Evommune (EVMN) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. Evommune's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Evommune (EVMN), the current Other Stockholders Equity is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evommune Business Description

Address 1841 Page Mill Road, Suite 100, Palo Alto, CA, USA, 94304
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
10GF Score

Get the complete analysis for EVMN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.12
Price